Shares of Gilead Sciences moved up yesterday on the news that its new HIV combo drug dubbed Quad was just as effective as the popular Atripla in a mid-stage trial. Quad combines the approved Truvada therapy with two new agents: elvitegravir and cobicistat. Gilead's stock jumped 4 percent on the news. Report